Balance Sheet

Cash Flow Statement

Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Inventory Change in Inventory Change in Receivables Change in Receivables Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Share-based Compensation Share-based Compensation Shares Issued Short-Term Debt issuances

Daily Values

Growth Metrics

Others

Neuroone Medical Technologies (NMTC) Amortization of Deferred Charges (2016 - 2024)

Neuroone Medical Technologies' Amortization of Deferred Charges history spans 3 years, with the latest figure at $192647.0 for Q4 2024.

For Q4 2024, Amortization of Deferred Charges changed N/A year-over-year to $192647.0; the TTM value through Sep 2025 reached $192647.0, changed N/A, while the annual FY2025 figure was $192647.0, 90.12% up from the prior year.
Amortization of Deferred Charges reached $192647.0 in Q4 2024 per NMTC's latest filing, down from $284637.0 in the prior quarter.
In the past five years, Amortization of Deferred Charges ranged from a high of $192647.0 in Q4 2024 to a low of $192647.0 in Q4 2024.